Bratislava Medical Journal Vol.116, No.1, p.11-14, 2016

Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.5

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.116, No.1, p.11-14, 2016
Title: Risk of tuberculosis in patients treated with biological medicines
Author: J. Homolka

Abstract: OBJECTIVE: The number of medicines used for biological therapy is constantly increasing. Biologic medicines selectively block the immunological processes leading to autoimmune manifestations with tissue damage or block the progression of haemato-oncological or other malignancies. Biological medicines are usually monoclonal antibodies or inhibitors of certain cytokines, cell receptors and enzymes. Their administration results in immunosuppression associated with increased risk of infectious complications, including tuberculosis. Assessment of the risk of tuberculosis associated with biological medicines is an important part of the medical decision done by pneumologist. We describe the risks of different biologicals and suggest the possible necessary steps in evaluating the risk of tuberculosis in individual patient (Ref. 18).

Keywords: tuberculosis, latent tuberculosis infection, biological medicine, screening, chemoprevention
	Published online: 21-Jan-2016
Year: 2016, Volume: 116, Issue: 1	Page From: 11, Page To: 14
doi:10.4149/BLL_2016_002
	download file

Aepress.sk